A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy
Advanced Science · 2023
DOI: 10.1002/advs.202300116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Rui Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Ch…. Hauptthemen laut MEDLINE: Dendrimers, Cancer Vaccines. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Natural Science Foundation of Sichuan Province, the 1.3.5 project for disciplines of excellence,West China Hospital, Sichuan University.
Abstract (Originalsprache)
The clinical efficacy of personalized cancer vaccines still needs to be improved due to their insufficient immune effect. The development of innovative adjuvants and lymph node‐targeted delivery systems is the key to improving the clinical efficacy of personalized vaccines. However, there is still a lack of an adjuvant delivery system that is simple in preparation and capable of mass production and integrates adjuvant and lymph node targeted delivery functions. Here, this work reports that a simple dendrimer polypeptide (KK2DP7) nanoparticle enhances the immune efficacy of an OVA/neoantigen‐based vaccine. Due to its multiple functions as a delivery vehicle, immune adjuvant, and facilitator of dendritic cell migration, KK2DP7 efficiently increases the efficiency of antigen uptake and cross‐presentation by antigen‐presenting cells (APCs) and delivers antigens to lymph nodes via APCs. Strikingly, the antitumor effect of KK2DP7/OVA is superior to that of commonly used adjuvants such as poly(I:C), CpG, and aluminum adjuvant combined with OVA. Furthermore, KK2DP7/OVA combined with anti‐PD‐1 antibody is able to prevent tumor recurrence in a postoperative recurrent tumor model. Thus, KK2DP7‐based cancer vaccines alone or in combination with immune checkpoint blockade therapies to treat tumors or postoperative tumor recurrence are a powerful strategy to enhance antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China.
ORCID-Profile: Li Yang
Förderung
- National Natural Science Foundation of China
- National Natural Science Foundation of Sichuan Province
- the 1.3.5 project for disciplines of excellence,West China Hospital, Sichuan University
Zitieren
APA
Zhang, R., Tang, L., Wang, Y., Tian, Y., Wu, S., Zhou, B., Dong, C., Zhao, B., Yang, Y., Xie, D., & Yang, L. (2023). A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202300116
Vancouver
Zhang R, Tang L, Wang Y, Tian Y, Wu S, Zhou B, et al. A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy. Advanced Science. 2023. doi:10.1002/advs.202300116
BibTeX
@article{Zhang2023,
author = {Zhang, Rui and Tang, Lin and Wang, Yusi and Tian, Yaomei and Wu, Siwen and Zhou, Bailing and Dong, Chunyan and Zhao, Binyan and Yang, Yuling and Xie, Daoyuan and Yang, Li},
title = {A Dendrimer Peptide (KK2DP7) Delivery System with Dual Functions of Lymph Node Targeting and Immune Adjuvants as a General Strategy for Cancer Immunotherapy},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202300116}
}
EUVIMED